Publications by authors named "G Armagan"
Sunitinib, a multi-targeted tyrosine kinase inhibitor, is prescribed for the treatment of metastatic gastrointestinal stromal tumors, advanced metastatic renal cell carcinoma, and pancreatic neuroendocrine tumors. Hepatotoxicity and nephrotoxicity are significant adverse effects of sunitinib administration; however, there is limited information regarding the molecular mechanisms of these adverse effects. The aim of the present study was to elucidate the role of endoplasmic reticulum stress in hepatotoxicity and nephrotoxicity induced by sunitinib.
View Article and Find Full Text PDFArticle Synopsis
- * The study identifies a direct interaction between GLT-1 and Presenilin 1 (PS1), revealing that GLT-1 can lower amyloid-beta (Aβ) production by altering γ-secretase activity, thereby affecting how amyloid precursor protein (APP) is processed.
- * Targeting the GLT-1/PS1 interaction may serve as a promising new therapeutic approach to manage AD, as inhibiting this interaction increases Aβ levels, suggesting its critical role in disease progression.*
Objectives: In recent years, there has been a growing interest in targeting ferroptosis for the treatment and prevention of multiple cancers. This study aimed to assess the contribution of ferroptosis to the antiproliferative effects of genistein (GN) and daidzein (DZ) in breast cancer cell lines.
Methods: MDA-MB-231 and MCF-7 cells were employed as an in vitro model.
Objectives: Previous studies have shown that gene expressions can be regulated in the hippocampus of rats after seizures induced by kainic acid (KA). The aim of this study was to examine the potential regulatory impact of KA administration on gene expression levels of enzymes responsible for drug metabolism in rat hippocampal tissue.
Materials And Methods: Rats received intraperitoneal injections of KA and saline at a dose of 10 mg/kg.
Correction: Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.
Naunyn Schmiedebergs Arch Pharmacol
November 2024